NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARC
NCT07898865
Summary
This is a prospective, randomized, multicenter phase II trial evaluating neoadjuvant CAPOX chemotherapy combined with the PD-1 inhibitor serplulimab administered either before or after short-course radiotherapy (SCRT) in patients with locally advanced rectal cancer. The primary endpoint is the complete response (CR) rate, defined as pathological complete response (pCR) plus clinical complete response (cCR). Secondary endpoints include safety, perioperative outcomes, survival, recurrence patterns, and integrated multi-omics analyses of paired tumor samples. The study aims to determine the optimal sequencing strategy and identify immune microenvironmental biomarkers predictive of response.
Eligibility
Inclusion Criteria: * Age 18-70 years, any sex. * Clinical stage II/III rectal adenocarcinoma (cT3-T4N0 or cT2-T4N+, M0) according to AJCC 8th edition. * Tumor located ≤10 cm from anal verge (confirmed by colonoscopy or digital rectal exam). * Histologically confirmed rectal adenocarcinoma. * ECOG performance status 0-1. * Adequate organ function: * Hemoglobin ≥90 g/L; WBC ≥3.5×10⁹/L; ANC ≥1.5×10⁹/L; Platelets ≥100×10⁹/L. * Serum creatinine, BUN ≤1.0×ULN. * ALT, AST, ALP ≤1.5×ULN; Total bilirubin ≤1.5×ULN. * Negative urine protein; normal coagulation. * No known allergy to fluoropyrimidines or platinum. * No prior surgery (except diverting colostomy), chemotherapy, or radiotherapy for primary rectal cancer. * No prior pelvic radiotherapy. * Signed written informed consent. Exclusion Criteria: * Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors, or other investigational immunotherapies. * Active autoimmune disease (e.g., Crohn's disease, ulcerative colitis, rheumatoid arthritis, scleroderma, SLE, vasculitis). * Symptomatic interstitial lung disease or active pneumonia. * GI conditions increasing risk of perforation (e.g., active diverticulitis, abscess, obstruction). * History of other malignancies, except cured non-melanoma skin cancer or in situ cervical cancer. * Active infections, uncontrolled heart failure, recent myocardial infarction (\<6 months), unstable angina, or severe arrhythmia. * Other uncontrolled disease or condition that may interfere with study participation. * Pregnancy or lactation. * Known immunodeficiency (e.g., HIV) or history of organ/allo-HSCT transplantation. * Active HBV (HBV DNA ≥2000 IU/mL), HCV infection, or active tuberculosis. * Receipt of cancer vaccines or live vaccines within 4 weeks prior to enrollment (seasonal inactivated influenza vaccines allowed). * Concurrent use of other investigational agents, long-term corticosteroids, or immunosuppressants. * Psychiatric disorders, substance abuse, or social conditions limiting compliance. * Known allergy or contraindication to study drugs.
Conditions3
Interventions2
Related trials
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. — RemeGen Co., Ltd.
- A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy — Fudan University
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC — Shanghai Henlius Biotech
- A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors — Shanghai Henlius Biotech
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer — MediLink Therapeutics (Suzhou) Co., Ltd.
- A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study — Fudan University
- Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer — Fudan University
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC — Fujian Medical University Union Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07898865